H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $9
H.C. Wainwright analyst Mitchell Kapoor maintains $Century Therapeutics(IPSC.US)$ with a buy rating, and adjusts the target price from $11 to $9.According to TipRanks data, the analyst has a success
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $9
Century Therapeutics Analyst Ratings
Buy Rating for Century Therapeutics Amidst Shift in Cell Therapy Market and Safety Concerns of Competitors
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cronos Group (CRON), Relay Therapeutics (RLAY) and Century Therapeutics (IPSC)